KalVista Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference
08 août 2017 07h30 HE
|
KalVista Pharmaceuticals, Inc.
CAMBRIDGE, Mass. and PORTON DOWN, United Kingdom, Aug. 08, 2017 (GLOBE NEWSWIRE) -- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery,...
KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Fourth Quarter and Full Year Financial Results
27 juil. 2017 16h01 HE
|
KalVista Pharmaceuticals, Inc.
– Oral Plasma Kallikrein Inhibitor Portfolio for Treatment of Hereditary Angioedema Continues to Advance – – Intravitreal Diabetic Macular Edema Phase 2 On Track to Initiate in 2017 – CAMBRIDGE,...
KalVista Pharmaceuticals to Present at Jefferies Healthcare Conference
01 juin 2017 07h30 HE
|
KalVista Pharmaceuticals, Inc.
CAMBRIDGE, Mass. and PORTON DOWN, United Kingdom, June 01, 2017 (GLOBE NEWSWIRE) -- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery,...
KalVista Pharmaceuticals Reports Fiscal Third Quarter Results
16 mars 2017 16h15 HE
|
KalVista Pharmaceuticals, Inc.
– Continuing to Develop a Portfolio of Oral Plasma Kallikrein Inhibitors for HAE –– Intravitreal DME Program Remains on Track for Phase 2 in 2017 –– Company Expects to be Well-Funded Through...
KalVista Pharmaceuticals Appoints Edward P. Feener, Ph.D. as Chief Scientific Officer
29 nov. 2016 07h30 HE
|
KalVista Pharmaceuticals, Inc.
CAMBRIDGE, Mass. and PORTON DOWN, United Kingdom, Nov. 29, 2016 (GLOBE NEWSWIRE) -- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery,...
KalVista Pharmaceuticals Announces Closing of Merger with Carbylan Therapeutics
22 nov. 2016 07h30 HE
|
KalVista Pharmaceuticals Ltd
—Combined company renamed KalVista Pharmaceuticals, Inc., listed on Nasdaq with ticker “KALV” — —Continued focus on development of protease inhibitors with multiple molecules for oral treatment of...